177 related articles for article (PubMed ID: 30133806)
1. Long-term results of the risk-stratified treatment of childhood acute lymphoblastic leukemia in China.
Shen S; Cai J; Chen J; Xue H; Pan C; Gao Y; Tang Y; Wang J; Li B; Wang X; Chen J; Gu L; Tang J
Hematol Oncol; 2018 Oct; 36(4):679-688. PubMed ID: 30133806
[TBL] [Abstract][Full Text] [Related]
2. [Long-term results of multicenter study based on childhood acute lymphoblastic leukemia 2005 protocol].
Cai JY; Wang NL; Jiang H; Shen SH; Xue HL; Chen J; Pan C; Gao YJ; Sun LR; Yuan XJ; Gu LJ; Tang JY
Zhonghua Er Ke Za Zhi; 2018 Jul; 56(7):511-517. PubMed ID: 29996184
[No Abstract] [Full Text] [Related]
3. [Multi-center trial based on SCMC-ALL-2005 for children's acute lymphoblastic leukemia].
SHAQ Multicenter Study Group of Children's Acute Lymphoblastic Leukemia Research
Zhonghua Er Ke Za Zhi; 2013 Jul; 51(7):495-501. PubMed ID: 24267129
[TBL] [Abstract][Full Text] [Related]
4. [Long-term outcome of childhood T-cell acute lymphoblastic leukemia treated with modified national protocol of childhood leukemia in China-acute lymphoblastic leukemia 2008].
Liao C; Shen DY; Xu XJ; Xu WQ; Zhang JY; Song H; Yang SL; Zhao FY; Shen HP; Tang YM
Zhonghua Er Ke Za Zhi; 2020 Sep; 58(9):758-763. PubMed ID: 32872717
[No Abstract] [Full Text] [Related]
5. Prediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China.
Wei W; Chen X; Zou Y; Chang L; An W; Wan Y; Liu T; Yang W; Chen Y; Guo Y; Zhu X
BMC Pediatr; 2015 Jul; 15():80. PubMed ID: 26174476
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of acute lymphoblastic leukemia in young children treated by the SCMC-ALL-2009 protocol.
Liu K; Chu J; Dai Y; Jiang A; Yang L; Xie Z; Zhang K; Tu S; Cai H; Wu Z; Wang N
Leuk Lymphoma; 2020 Dec; 61(12):2850-2858. PubMed ID: 32643496
[TBL] [Abstract][Full Text] [Related]
7. [Evaluation on protocol SCMS-ALL-2005 for childhood B lineage acute lymphoblastic leukemia].
Tang JY; Xue HL; Chen J; Pan C; Li BS; Gu LJ; Dong L; Hu WT; Shen SH; Zhou M; Ye QD; Jiang H; Luo CY
Zhonghua Yi Xue Za Zhi; 2012 Feb; 92(8):546-50. PubMed ID: 22490159
[TBL] [Abstract][Full Text] [Related]
8. [A collaborative study of children with lymphoblastic non-Hodgkin's lymphoma in China].
;
Zhonghua Er Ke Za Zhi; 2015 Dec; 53(12):931-7. PubMed ID: 26887549
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy.
Pui CH; Pei D; Raimondi SC; Coustan-Smith E; Jeha S; Cheng C; Bowman WP; Sandlund JT; Ribeiro RC; Rubnitz JE; Inaba H; Gruber TA; Leung WH; Yang JJ; Downing JR; Evans WE; Relling MV; Campana D
Leukemia; 2017 Feb; 31(2):333-339. PubMed ID: 27560110
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of Adults with Acute Lymphoblastic Leukemia After Autologous Hematopoietic Stem Cell Transplantation and the Significance of Pretransplantation Minimal Residual Disease: Analysis from a Single Center of China.
Ding Z; Han MZ; Chen SL; Ma QL; Wei JL; Pang AM; Zhang XY; Liang C; Yao JF; Cao YG; Feng SZ; Jiang EL
Chin Med J (Engl); 2015 Aug; 128(15):2065-71. PubMed ID: 26228220
[TBL] [Abstract][Full Text] [Related]
11. Clinical value of pre-transplant minimal residual disease in childhood lymphoblastic leukaemia: the results of the French minimal residual disease-guided protocol.
Gandemer V; Pochon C; Oger E; Dalle JH; Michel G; Schmitt C; de Berranger E; Galambrun C; Cavé H; Cayuela JM; Grardel N; Macintyre E; Margueritte G; Méchinaud F; Rorhlich P; Lutz P; Demeocq F; Schneider P; Plantaz D; Poirée M; Bordigoni P
Br J Haematol; 2014 May; 165(3):392-401. PubMed ID: 24479958
[TBL] [Abstract][Full Text] [Related]
12. [Long-term follow-up of childhood low-risk ALL patients treated with SCMC-ALL-2005 protocol].
Hu WT; Xue HL; Chen J; Pan C; Shen SH; Zhou M; Ye QD; Jiang H; Luo CY; Tang YJ; Wang JM; Gu LJ; Tang JY
Zhonghua Xue Ye Xue Za Zhi; 2013 Oct; 34(10):834-8. PubMed ID: 24171955
[TBL] [Abstract][Full Text] [Related]
13. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
14. Minimal Residual Disease-guided Risk Restratification and Therapy Improves the Survival of Childhood Acute Lymphoblastic Leukemia: Experience From a Tertiary Children's Hospital in China.
Liao C; Xu X; Shen D; Song H; Xu W; Zhao F; Yang S; Shi S; Liang J; Li S; Tang Y
J Pediatr Hematol Oncol; 2019 Aug; 41(6):e346-e354. PubMed ID: 30640823
[TBL] [Abstract][Full Text] [Related]
15. Treatment outcome of young children with acute lymphoblastic leukaemia: achievements and directions implied from Shanghai Children's Medical Centre based SCMC-ALL-2005 protocol.
Liang Y; Yang LH; Jiang H; Yuan XJ; Sun LR; Wang NL; Tang JY
Br J Haematol; 2015 Apr; 169(2):267-77. PubMed ID: 25655921
[TBL] [Abstract][Full Text] [Related]
16. [Monitoring of minimal residual disease in children with acute lymphoblastic leukemia and its prognostic significance].
Xu XJ; Tang YM; Song H; Shi SW; Yang SL; Shen HQ; Wei J; Xu WQ; Pan BH; Zhao FY
Zhonghua Er Ke Za Zhi; 2010 Mar; 48(3):180-4. PubMed ID: 20426951
[TBL] [Abstract][Full Text] [Related]
17. Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group.
Pieters R; de Groot-Kruseman H; Van der Velden V; Fiocco M; van den Berg H; de Bont E; Egeler RM; Hoogerbrugge P; Kaspers G; Van der Schoot E; De Haas V; Van Dongen J
J Clin Oncol; 2016 Aug; 34(22):2591-601. PubMed ID: 27269950
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic significance and risk factors of minimal residual disease ≥1% on 19th day of induction chemotherapy in children with acute lymphoblastic leukemia].
Yu J; Yi T; Lin G; Wen J; Chen L; Chen J; Wu X
Nan Fang Yi Ke Da Xue Xue Bao; 2020 Feb; 40(2):255-261. PubMed ID: 32376526
[TBL] [Abstract][Full Text] [Related]
19. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group.
Eckert C; Henze G; Seeger K; Hagedorn N; Mann G; Panzer-Grümayer R; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Schrauder A; Escherich G; Sramkova L; Niggli F; Hitzler J; von Stackelberg A
J Clin Oncol; 2013 Jul; 31(21):2736-42. PubMed ID: 23775972
[TBL] [Abstract][Full Text] [Related]
20. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia.
Schmiegelow K; Forestier E; Hellebostad M; Heyman M; Kristinsson J; Söderhäll S; Taskinen M;
Leukemia; 2010 Feb; 24(2):345-54. PubMed ID: 20010622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]